Context Therapeutics (NASDAQ:CNTX) Stock Rating Upgraded by Citizens Jmp

Context Therapeutics (NASDAQ:CNTX) was upgraded by investment analysts at Citizens Jmp to a “strong-buy” rating in a note issued to investors on Wednesday,Zacks.com reports.

Several other equities analysts also recently commented on the stock. HC Wainwright restated a “buy” rating and set a $6.00 target price on shares of Context Therapeutics in a research report on Monday, September 23rd. D. Boral Capital assumed coverage on shares of Context Therapeutics in a research note on Monday, November 25th. They issued a “buy” rating and a $9.00 price target on the stock. Finally, JMP Securities started coverage on Context Therapeutics in a report on Wednesday. They issued an “outperform” rating and a $4.00 target price on the stock. Six research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $6.33.

Context Therapeutics Stock Performance

NASDAQ:CNTX opened at $1.21 on Wednesday. The stock has a 50-day simple moving average of $1.52 and a two-hundred day simple moving average of $1.94. The firm has a market capitalization of $90.75 million, a PE ratio of -1.33 and a beta of 2.10. Context Therapeutics has a 52-week low of $0.89 and a 52-week high of $2.75.

Context Therapeutics (NASDAQ:CNTX) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.11). Equities analysts forecast that Context Therapeutics will post -0.51 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Context Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Y Intercept Hong Kong Ltd bought a new position in Context Therapeutics during the 3rd quarter valued at about $89,000. Renaissance Technologies LLC grew its stake in shares of Context Therapeutics by 63.4% during the second quarter. Renaissance Technologies LLC now owns 65,200 shares of the company’s stock valued at $131,000 after buying an additional 25,300 shares during the last quarter. State Street Corp raised its holdings in shares of Context Therapeutics by 21.5% in the third quarter. State Street Corp now owns 111,907 shares of the company’s stock worth $219,000 after buying an additional 19,800 shares during the period. Affinity Asset Advisors LLC lifted its stake in shares of Context Therapeutics by 392.4% during the 2nd quarter. Affinity Asset Advisors LLC now owns 1,619,140 shares of the company’s stock worth $3,246,000 after acquiring an additional 1,290,323 shares during the last quarter. Finally, Franklin Resources Inc. purchased a new position in Context Therapeutics during the 3rd quarter valued at $3,689,000. Hedge funds and other institutional investors own 14.03% of the company’s stock.

Context Therapeutics Company Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.